December 21, 2014 9:47 PM ET

Healthcare Providers and Services

Company Overview of Genzyme Polyclonals S.A.S.

Company Overview

Genzyme Polyclonals S.A.S. operates as a subsidiary of Genzyme Corporation.

Les Carrés du Parc

10 rue des Rosiéristes - BP 54

Champagne au Mont D´Or

Rhone,  69543

France

Phone:

33 4 37 28 16 00

Fax:

33 4 37 28 16 79

Key Executives for Genzyme Polyclonals S.A.S.

Chief Executive Officer and Chief Operating Officer
Age: 59
Compensation as of Fiscal Year 2014.

Genzyme Polyclonals S.A.S. Key Developments

Genzyme and Isis Pharmaceuticals Inc. Present Kynamro Clinical Data at the American Heart Association

Genzyme and Isis Pharmaceuticals Inc. announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. This retrospective analysis included 104 patients who enrolled in the long-term extension study of KYNAMRO after having completed one of the KYNAMRO phase 3 blinded, randomized, placebo-controlled 6-month trials in patients with homozygous and heterozygous FH. All patients who completed at least two years of treatment with KYNAMRO were included in the analysis. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.

Genzyme Presents at Boston CEO Conference, Jun-05-2014 04:00 PM

Genzyme Presents at Boston CEO Conference, Jun-05-2014 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: David Meeker.

Genzyme Receives Complete Response Letter from Food and Drug Administration on Lemtrada(TM) (alemtuzumab) Application

Genzyme announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A complete response letter informs companies that an application is not ready for approval. FDA has taken the position that the company has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects. The company understands that the conclusion is related to the design of the completed Phase 3 active comparator studies of Lemtrada in relapsing-remitting MS patients. FDA has also taken the position that one or more additional active comparator clinical trials of different design and execution are needed prior to the approval of Lemtrada.

Similar Private Companies By Industry

Company Name Region
La Résidence Les Chesnais Europe
La Résidence des Coteaux Europe
Ouest Répartition SA Europe
Conceptus SAS Europe
La Méditerranée de La Franqui Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 10, 2014
Celsior Solution
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genzyme Polyclonals S.A.S., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.